Prenatal Screening for Imprinting Anomalies Implicated in Beckwith Wiedemann and Silver Russell Syndromes (DASIRUWIBE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01842659|
Recruitment Status : Active, not recruiting
First Posted : April 29, 2013
Last Update Posted : August 24, 2016
Losses of imprinting are involved in various syndromes. Those occurring in the 11p15 region lead to Beckwith-Wiedemann and Silver-Russell Syndromes. These losses of imprinting follow a mosaic pattern, rendering their detection difficult, especially given the scarcity of available DNA in amniotic fluid. Thus, in spite of growing demand, prenatal diagnosis (PND) for imprinting abnormalities of the 11p15 region is not available.
The recent development of a quantitative PCR method that permits the methylation index (MI) of imprinted regions to be calculated renders PND technically possible. Nevertheless, because of the mosaic nature of these anomalies, it is essential to verify that the methylation pattern of the 11p15 region obtained from the amniotic fluid matches that obtained from the blood.
|Condition or disease||Intervention/treatment||Phase|
|Pregnant Women Requiring Amniocentesis||Genetic: Methylation Index||Not Applicable|
To evaluate the agreement between the methylation index of the 11p15 region obtained using DNA extracted from amniocytes and that extracted from cord blood leukocytes, by calculating the intraclass correlation coefficient (ICC).
Ancillary study :
This second part of the study aims to determine the standard of methylation index of the 11p15 region (inclusion of 100 additional patients). The use of amniotic liquid will allow to calculate :
- the average of methylation index,
- the value of the standard deviation
- the inter-assay coefficient of variation for the test-used.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||67 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Prenatal Screening for Imprinting Anomalies Implicated in Beckwith Wiedemann and Silver Russell Syndromes|
|Study Start Date :||May 2013|
|Actual Primary Completion Date :||December 2015|
|Estimated Study Completion Date :||October 2016|
Experimental: Pregnant women requiring amniocentesis
Pregnant women requiring amniocentesis
Genetic: Methylation Index
To calculate the methylation index (MI) of imprinted regions.
- Methylation Index (MI) of the 11p15 region using DNA extracted [ Time Frame: 27 weeks ]To evaluate the agreement between the MI of the 11p15 region obtained using DNA extracted from amniocytes and that extracted from cord blood leukocytes, by calculating the intraclass correlation coefficient (ICC).
- MI using the placenta [ Time Frame: 27 weeks ]To calculate the MI using the placentas of the same individuals and to evaluate its agreement with the MIs obtained above.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01842659
|Explorations fonctionnelles endocriniennes|
|Paris, France, 75012|
|Principal Investigator:||Irene Netchine, PU-PH||Assistance Publique|